Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Ketamine in Sickle Cell Disease Pain Crisis
NCT07450430Phase 3Not yet recruiting
- Sponsor
- Boston Children's Hospital
- Start
- Feb 2026
- Primary completion
- Feb 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ketamine in sickle cell disease (SCD), sponsored by Boston Children's Hospital. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
ketamine
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT07450430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07450430.